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Abstract
Background: Gastric cancer is a considerable burden for worldwide patients. And diffuse gastric cancer is the most
insidious subgroup with poor survival. The phenotypic characterization of the diffuse gastric cancer cell line can be
useful for gastric cancer researchers. In this article, we aimed to characterize the diffuse gastric cancer cells with MRI
and transcriptomic data. We hypothesized that gene expression pattern is associated with the phenotype of the
cells and that the heterogeneous enhancement pattern and the high tumorigenicity of SNU484 can be modulated
by the perturbation of the highly expressed gene.
Methods: We evaluated the 9.4 T magnetic resonance imaging and transcriptomic data of the orthotopic mice
models from diffuse gastric cancer cells such as SNU484, Hs746T, SNU668, and KATO III. We included MKN74 as an
intestinal cancer control cell. After comprehensive analysis integrating MRI and transcriptomic data, we selected
CD34 and validated the effect by shRNA in the BALB/c nude mice models.
Results: SNU484, SNU668, Hs746T, and MKN74 formed orthotopic tumors by the 5 weeks after cell injection. The
diffuse phenotype was found in the SNU484 and Hs746T. SNU484 was the only tumor showing the heterogeneous
enhancement pattern on T2 images with a high level of CD34 expression. Knockdown of CD34 decreased the
round-void shape in the H&E staining (P = 0.028), the heterogeneous T2 enhancement, and orthotopic
tumorigenicity (100% vs 66.7%). The RNAseq showed that the suppressed CD34 is associated with the
downregulated gene-sets of the extracellular matrix remodeling.
Conclusion: Suppression of CD34 in the human-originated gastric cancer cell suggests that it is important for the
round-void histologic shape, heterogeneous enhancement pattern on MRI, and the growth of gastric cancer cell
line.
Keywords: Diffuse gastric cancer, CD34, Knockdown, Magnetic resonance imaging, Histology, Phenotype, BALB/c
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Background
Gastric cancer (GCA) is the 5th most common neo-
plasm worldwide. And the incidence of GCA is pro-
found in South Korea, Mongolia, China, and Japan
[1]. Even though early detection of the tumor can
prolong the survival of patients [2, 3], about 33% of
patients with gastric cancer (GCA) are diagnosed with
diffuse GCA (DGCA) [4]. As the name implies,
DGCA infiltrates the contour of the stomach insidi-
ously, which lead to the incomplete resections. Some
portions of DGCA patients show a phenotype of
signet-ring cancer (SRC) [5], and the clinical signifi-
cance of the signet-ring shape is controversial [6–8].
Even with the importance of DGCA, its biological func-
tion is difficult to analyze in the animal orthotopic models,
which requires a microsurgical technique [9–11]. Further-
more, the characterization of the shape and the extent of
stomach cancer is one more difficulty. When the malicious
phenotypes of DGCA can be associated with the transcrip-
tomic data, more opportunities can be obtained in the re-
search of stomach cancer.
To resolve these unmet needs, we hypothesized that a
phenotype of DGCA is associated with the cell-specific gene
expression and that such phenotype can be suppressed by
the knockdown of the gene and thereby showing a tumor-




Human GCCs such as SNU484 (KCLB Cat# 00484, RRID:
CVCL_0100), SNU668 (KCLB Cat# 00668, RRID:CVCL_
5081), MKN74 (KCLB Cat# 80104, RRID:CVCL_2791),
Kato III (KCLB Cat# 30103, RRID:CVCL_0371), and
Hs746T ((KCB Cat# KCB 2013048YJ, RRID:CVCL_0333)
were purchased from the Korean Cell Line Bank (Seoul,
Korea). SNU-484, SNU-668, MKN-74, and Kato III were
grown in RPMI 1640 (Welgene, Daegu, Korea); Hs746T was
grown in Dulbecco’s modified Eagle’s medium (DMEM,
Welgene); All cells were cultured with 1% antibiotic-
antimycotic solution (including 10,000 units penicillin, 10
mg streptomycin, and 25 μg amphotericin B per mL, Sigma-
Aldrich) at 37 °C in a humidified atmosphere containing 5%
CO2. All cells were confirmed to be negative for myco-
plasma by e-Myco™ plus Mycoplasma PCR Detection Kit
(iNtRON Biotechnology, Seongnam, Korea). Cell lines were
supplemented with 10% FBS (Gibco) as the basis for the
analysis. Four replicates of each cell were introduced for
microarray data. These cell lines were used in the animal
experiments.
Invasion assay
2 × 104 HUVEC cells in a culture medium (M199) were
added to a transwell coated with fibronectin. The
bottom of the well was coated with 0.2% gelatin and
subsequently incubated for 48 h until the formation of a
monolayer. Then, 1 × 105/50 μL GCCs (SNU484,
SNU668, Hs746T, and other cells such as YCC1, YCC2,
YCC3, YCC6, YCC16, MKN28, AGS) with CellTracker™
(Molecular Probes, C2925) without FBS were separately
added to the transwell. Culture medium with 10% FBS
was added to the lower chamber. After incubation for
48 h, the upper cells of the membrane were removed
with a cotton swab. Cells on the lower membrane were
lysed with 200 μL lysis buffer for 2–3 h at room
temperature. Fluorescence was measured with Ex/Em
492/517.
Animal models
All animal experiments were conducted with the ap-
proval of the Institutional Animal Care and Use Com-
mittee of the Yonsei Laboratory Animal center (IACUC
2017–0329). Four-week-old male BALB/c nude mice
(N = 60, average weight 22 ± 2 g) were purchased from
Orient Bio (Seongnam, South Korea). The sample size of
animal was based on the prior reports [12, 13]. After 1
week of acclimatization, each group of five mice is
housed in the separated individual standard cleaned
cages under automatically controlled air condition sys-
tem with temperature (22 ± 2 °C), humidity (about 60%),
and lighting (12:12-h light–dark cycle). Diet and steril-
ized water are provided ad libitum throughout the ex-
periments. Mice were modeled simultaneously for
orthotopic and heterotopic site after randomization of
the size of the mice. After all images were taken for the
specified models, the mice were euthanized with CO2,
and the collected stomach samples were sent for H&E
staining.
Orthotopic mice model
Orthotopic modeling required operation with anesthesia
(Isoflurane 2%) [14]. Cells were injected (1 × 107 GCCs/
30 μl PBS, 29G insulin syringe) into the walls of the ex-
teriorized stomachs of BALB/c nude mice (male) by in-
cising the skin and peritoneum along the upper midline
for approximately 5 mm following the method. The
stomach was returned to the peritoneum, and the ab-
dominal wall was closed with a wound suture in one
layer.
Heterotopic xenograft mice model
1 × 107 GCCs were transplanted into the proximal thigh
region of BALB/c nude mice (male), and we observed
the model until the tumor volume expanded up to 4000
mm3. Implanted tumor size was assessed three times per
week and calculated by (4/3) × π × (minor axis/
2)2 × (major axis/2) mm3. Tumorigenicity was measured
in the third week after injecting the cells (n = 10 per
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group). We plotted the KM plot not by the survival of
the mice but by the 4-fold size change from the initial
measurement as the event. If the diagonal tumor size
was larger than 2 cm, the mice were euthanized with
CO2.
Animal magnetic resonance imaging
Mice were imaged on a 9.4 T animal MRI with a Bruker
animal coil (RF SUC 400 1H M-BR-LIN ROAD, Bruker
Medical Systems, Massachusetts, USA) after anesthesia
with isoflurane (2% maintained throughout the study
with nose cone). Each mouse was kept at approximately
37 °C while in the scanner. Mice were scanned during
the day time (light cycle) two to four times during the
orthotopic model imaging depending on the established
cell types (SNU484, First image 2 weeks after injection,
three times with a week interval; SNU668 first image 1
week after injection, four times images with 1 to 2-week
interval; Hs746T image was taken once 19 days after in-
jection; MKN74 first image 17 days after injection, four
times with a week interval; Kato III first image 4 weeks
after injection, two times with 1-week interval). Se-
quences were adopted at room temperature with the fol-
lowing parameters: Echo = 1, TR = 2300 ms, TE = 22.0
ms, FA = 180 deg, TA = 0 h 4m 54 s 400 ms, NEX = 2,
and FOV = 4.00 cm. After taking the MR image, mice
were sent back to the same cleaned cage.
Knockdown of CD34
Lentiviral particles (CD34 shRNA particle; sc-29,249 V,
Control shRNA particle; sc-108,080, Santa Cruz Biotech-
nology, USA) for CD34 suppression were purchased
from Santa Cruz. There are three groups in this experi-
ment: wildtype (SNU484 WT), scramble shRNA control
(SNU484 SC), and CD34 knockdown cells (SNU484
KD). SNU484 WT cell line was plated on the 12-well
plate 24 h prior to the infection for 50% confluence on
day 2. Polybrene pretest was maintained far below 5 μg/
ml. Lentiviral shRNA was transfected on day two follow-
ing the manufacturer’s instructions. Puromycin-resistant
clones were subcultured and expanded, and CD34 ex-
pression was assessed. Mice models were established
using SNU484 SC and SNU484 KD (Five mice for each
group, Same setting with a replication, Total twenty
mice).
Tumorsphere formation assay
We compared the tumorsphere formation between
SNU484 SC and SNU484 KD. In 96-well plates, ten cells
of each type were cultured in 50 μL DMEM/F12 (Gibco)
supplemented with bFGF, EGF, B27, 10% FBS, and 1%
antibiotics. After 30 days of incubation, spheres in each
well were counted for statistical comparison.
Migration assay
Three types of SNU484 cells were grown in monolayers
in culture media, with 10% FBS and 1% antibiotics.
When the confluency reached 70%, cell monolayers were
scratched with a 100 μL pipette tip. Wound width was
measured after 72 h and then normalized by wound
width measured immediately after scratching.
Drug sensitivity agents
Three types of cells were cultured for a drug sensitivity
experiment: SNU484 WT, S484 SC, and S484 KD with
RPMI media as a negative control. S484 WT (1 × 104
cells/well) cells in 96-well plates were treated with 100 μl
of 5- Fluorouracil (5-FU, Sigma, Cat. F6627-5G) at a
concentration of 155 μM with RPMI 1640 and without
FBS. 5-FU was dissolved in DMSO. Oxaliplatin 100 μl
was administered at a concentration of 5 μM. The com-
bination of the drug is 100 μl of each drug (0.07 μl of 5-
FU, 0.04 μl of oxaliplatin). Drug sensitivity was measured
with CCK at 24 h, 48 h, and 72 h after treatment with
the drugs.
H&E staining
Histology sections were compared among the SNU484
SC, SNU484 KD, MKN74, and SNU668 and they were
magnified (100 X) using the image software Olyvia 2.5
(Olympus) with the image field size of 1186 px by 668
px for a single analysis. H&E staining of the samples was
thoroughly examined. SNU484 SC, and SNU484 KD
were compared to assess the growth patterns and signet-
ring phenotypes.
Human microarray
The microarray (Illumina HT12 v3, United States) of
GCA patients of Severance Hospital (Republic of Korea,
Seoul, from 2000 to 2010, IRB 4–2016-0013) was ana-
lyzed for the effects and the associations of molecular
markers [15]. A pathologist and surgeon both confirmed
the Lauren classification and tumor size. TNM staging
was designated according to the AJCC 8th edition. Hist-
ology was divided into Moderately-differentiated (MD),
Poorly-differentiated (PD), Signet-ring carcinoma (SRC),
Well-differentiated (WD).
RNA sequencing
We collected samples of SNU484 WT, SNU484 SC, and
SNU484 KD and compared differential gene expression
among these samples. The sequencing platform is Hiseq
2500 with total RNA prepped with Truseq stranded total
RNA H/M/R prep kit (Illumina, United States). Diffuse
gastric cancer cells, SNU484 and Hs746T were revali-
dated with an RNAseq (Novaseq6000) prepared with the
TruseqStranded mRNA Prep Kit. Tophat (version
2.0.13) was used to map the FASTA on the hg19 human
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reference chromosome for both RNAseq analysis. FPKM
data was obtained using cufflink (Version 2.2.0) with a
mapping rate of more than 87%.
Data analysis
By using the expression level of CD34 in the tumor pa-
tients, we summarized the clinical variables. We com-
pared the Cox hazard ratio for CD34, which is adjusted
for age, sex, Charlson comorbidity score (CCI), tumor
size, location, Lauren classification, histologic type, and
AJCC TNM stage (8th edition) according to each se-
lected subgroup. Two-sided Student t-test was used for
the analysis. For gene extraction, we used the Elastic-
net algorithm and t-test [16].
Data availability
All the patient microarray data analyzed in this study are
open to the public and can be downloaded from GEO
(Yonsei gastric cancer cohort, YGC, GSE84433; Cell line
microarray GSE146361).
Result
The tumorigenic potential of cell lines
Our research begins with a hypothesis that diffuse gas-
tric cancer cells (DGCA GCCs) will form a diffuse infil-
trating tumor in the mice model. We selected DGCA
GCCs from commercially available sources. DGCA
GCCs such as SNU484, Hs746T, SNU668, and KATO
III were included for our study. Intestinal type GCC
MKN74 was used as a control. We evaluated the
tumorigenic potential in the orthotopic BALB/c nude
mice model. All of the five cell lines could establish the
tumor in the heterotopic mice model at 2 weeks after in-
jection of cells more than 90% of the trials (Table S1).
We established an orthotopic mice model that exterior-
ized stomachs after excision of skin and peritoneum of
the mice under anesthesia. The same number of cells
were injected (1 × 107 GCCs/30 μl PBS), and the tumori-
genic potential decreased from the heterotopic model
(Fig. 1a, Table S1).
The robust tumorigenic cell was SNU484 (100%, 8/8
mice) followed by SNU668 (77.7%, 7/9), Hs746T (50%,
5/10 mice), and MKN74(71.4%, 5/7 mice). Kato III not
established any tumor in the orthotopic models while
showing 100% tumorigenicity in the heterotopic models
(Table S1). We assessed the radiologic pattern of ortho-
topic mice models with 9.4 T MRI T2 images (Fig. 1).
SNU484 (75%, 6/8 mice) and Hs746T (40%, 2/5 mice)
were the diffuse phenotype cells while SNU668 (14.3%,
1/7 mice) and MKN74 (0%, 0/5 mice) showed less than
50% of diffuse shape in the MRI up to 5 weeks of follow
up (Fig. 4a). Most distinctively, SNU484 showed a het-
erogeneous enhancement pattern in the T2 image with-
out contrast agent (Fig. 1).
Deconvolution of gastric cancer cells
We began with a hypothesis that diffuse gastric cancer
cell lines are molecularly different from other cell lines.
We used the elastic-net algorithm and student t-test to
find the cell-specific markers of DGCA GCCs (Fig. 2c,
Fig. 1 Tumorigenesis in the BALB/c mouse. a The overall tumorigenesis rate of orthotopic models. b 9.4 T MRI demonstrates the orthotopic
tumor 2 weeks after the injection. c The orthotopic models 4 weeks after the injection. d Growing size of tumors were measured with the MRI.
The same number of cells (1 × 107 cells) were injected to the stomach surface of BALB/c mice. MRI: Magnetic resonance imaging,
PI: Post-injection
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Fig. S11) [16]. We found CD34, ESM 1, and PECAM1
are differentially expressed in the SNU484 and Hs746T
cell lines (Fig. S1).
We explored the bulk tissue data and cell microarray
data, and we found a disparity between these two data-
bases. CD34 gene has been suspected as the gastric can-
cer cell marker, and it is associated with the
microvascular density and poorly differentiated histo-
logical type in the human [17, 18]. In the bulk gastric
cancer tissue microarray data, CD34 shows a high cor-
relation with other vascular markers, ESM 1 and
PECAM1 (Fig. 2a, b) [19–21]. The three pairs from the
three genes show statistically positive results (P < 0.0001,
N = 357). Histologic subtypes also showed statistical sig-
nificance (P < 0.0001) between CD34 and PECAM1. Two
other associations preserved significant results in the dif-
fuse, intestinal, other histologic types (P < 0.0001), and in
the mixed type (P < 0.01).
We estimated the Cox hazard ratio of CD34 level of
bulk GC samples, and it is associated with the survival
of GC patients (Table 1). Such association may be con-
tributed by the higher proportion of diffuse Lauren type
or the PD or SRC histologic type of GC in the subpopu-
lation (Table S2). We included different covariates to the
models, and the associations of CD34 and the survival
were robust in the models (Table S3). We also did
Fig. 2 Different expression patterns of three genes of gastric cancer. a High correlations among the three marker genes. b The microarray result
of YGC cohort. c Loss of the correlations among the three genes. d the result of Diffuse GCCs. GC: gastric cancer, GCCs: gastric cancer cells, ns:
statistically not significant
Table 1 Multivariate Cox hazard model of YGC cohort with
tissue expression of CD34 (N = 357)
VARIABLES N HR (95% CI) P value
Age
27–61 180 Reference
62–86 177 1.703 (1.244–2.331) < 0.001
Sex
Female 115 Reference
Male 242 1.195 (0.856–1.668) 0.296
Histology
MD 110 Reference
Other 75 1.248 (0.79–1.973) 0.342
PD 172 1.411 (0.981–2.029) 0.064
TNM 8th
I to IIB 112 Reference
IIIA 112 2.821 (1.741–4.573) < 0.001
IIIB to IV 133 5.142 (3.319–7.967) < 0.001
Chemotherapy
Yes 294 Reference
Other 63 2.593 (1.702–3.95) < 0.001
Microarray
CD34 Expression 357 1.241 (1.046–1.473) 0.014
MD moderately differentiated, PD poorly differentiated, TNM the
classification of malignant tumors, HR hazard ratio, CI confidence interval
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subgroup analysis and found CD34 level is more domin-
antly associated in the older age, poorly differentiated
histology, and the AJCC grade more than 3B (Table S4).
And such clinical characteristics lead us to hypothesize
that CD34 and these related markers (ESM 1 and
PECAM1) might be involved with a more malicious
phenotype of GC.
We assessed the cell microarray, CD34 expression
pattern of GCCs is decoupled from the tissue data
(Fig. 2c, d). CD34 and the other genes no longer
show any correlation except ESM 1 and PECAM1 in
the DGCA GCCs (Fig. 2c, P < 0.0001, R = 0.86) and all
GCCs (Fig. S2, P < 0.0001, R = 0.61).
The CD34 knockdown decreased tumorigenicity but not
altered the diffuse phenotype
As SNU484 robustly establishes the tumor in the ortho-
topic model than Hs746T (100% vs. 50%) with the het-
erogeneous enhancement on T2 MRI (Fig. 1), we
focused on SNU484 cells which expressed CD34 gene
higher than other cell lines (Fig. 3a). The elevated CD34
mRNA levels of SNU484 were replicated in the protein
level assays (Fig. 3b, Fig. S3, Fig. S4).
We used shRNA viral particles to suppress the level of
CD34 in the SNU484 cell line. Western blot and flow cy-
tometry showed a decreased expression of CD34 protein
level in the SNU484 CD34 KD (Knock-down) than the
CD34 SC (Scramble) and CD34 WT (Wildtype) (Fig. S3,
S4). SNU484 CD34 KD decreased tumorigenicity from
100 to 66.7% (Table S1), which is compatible with the
decreased tumorsphere forming potential than the CD34
SC (Fig. S5, P = 0.014). Migration capacity decreased in
the SNU484 CD34 KD than the SNU484 SC and
SNU484 WT (Fig. S6). However, when injected into the
BALB/c nude mice, the diffuse infiltrating pattern of
SNU484 remained in the multiple samples in the
SNU484 SC and SNU484 CD34 KD (Fig. S7) 40 days
after the orthotopic model establishment.
Unlike the gross infiltrating pattern in the MRI, the
size of the SNU484 CD34 KD slightly decreased from
the SNU484 SC in the heterotopic model (Fig. S8). The
survival curve that estimated the event as the point of
four-fold increase from the baseline of the heterotopic
tumor size showed no statistical significance (Fig. S9,
P = 0.051).
The round void shape decreased significantly after CD34
knockdown
A notable difference was found in the microscopic
evaluation of the SNU484 samples from other GCCs
(Fig. 4a lower panel). The SNU484 tumors were col-
lected 40 days after the establishment of the models.
SNU484 showed a round void shape (RVS) through the
slides, which resembles the signet-ring shape of clinical
samples (Fig. 4b). SNU484 CD34 KD showed no such
area with the RVS (Fig. 4c). We counted the H&E slides
and summarized the result in the lower panel of Fig. 4a.
SNU484 SC showed a mean of 39 RVS in a single field
(Standard deviation [SD] = 19.2 RVS/field). While
SNU484KD shows average of 1.3 RVS (SD = 2.0 RVS/
field) with a statistical difference from SNU484 SC (P =
0.028, N = 10). Other GCCs such as SNU668 and
MKN74 showed no signet-ring like shape in the
formalin-fixed slide of the in vivo tumor.
We assessed the gene expression pattern of SNU484
CD34KD genes by comparing it with the SNU484 WT
and SNU484 SC (Fig. 5). We assessed the downregulated
genes with the fold change more than two. In the Reac-
tome database [22], there are at least five top pathways
overlapped between the two results. Lysosphingolipid-
related pathways (S1PR1, LPAR2, and S1PR5) and extra-
cellular matrix-related pathways (COL4A5, MMP1,
MMP10, PLOD2, TIMP1, and COL21A1) were the
Fig. 3 CD34 expression in the diffuse gastric cancer cell lines. a Microarray gene expression. b CD34 microarray correlated with the CD34
antibody. GCCs: Gastric cancer cell lines
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dominantly downregulated in the CD34 KD SNU484
cells (Fig. 5). We included the details of genes in each
pathway in Table S5. However, such perturbation on
CD34 not change the drug responsibility against 5-FU or
oxaliplatin which are effective in human gastric cancer
patients (Fig. S10) [23].
Discussion
CD34 has been associated with the tissue vascularity
and poorly differentiated histologic aspects of human
GC [18]. However, the biological function of the gene
has not been evaluated in the GC. In this study, we
hypothesized that the knockdown of CD34 lead to a
phenotypic difference of the SNU484, a GCC with a
high level of CD34 expression. Our study found that
CD34 might be associated with the signet-ring shaped
histology of GC, which disappeared after the knock-
down of CD34 (Fig. 4).
Tissue vascularity of CD34 had been in the overlap-
ping domain of tissue stem cells and the hematopoietic
stem cells [17, 24]. We assessed tissue microarray data,
and it shows high correlations among the levels of CD34
expression and other vessel-related markers (Fig. 2a).
However, our study revealed that these markers are
decoupled in GCCs (Fig. 2c), and we compared two
DGCA GCCs, Hs746T and SNU484. Non-invasive im-
aging with 9.4 T MRI showed a robust pattern of the
tumorigenic potential of SNU484 from Hs746T (Fig. 1).
We focused on the SNU484 with a high level of CD34.
MRI T2 images showed a heterogeneous pattern of en-
hancement, a signal of compartmentalized fluid, which
disappeared after the knockdown of CD34 in the
SNU484 cells (Figs. 4, [25, 26]). Tissue H&E staining re-
vealed there is no definite vascular structure and red
blood cells in the in vivo tumor (Fig. 4). With these find-
ings, the void shape is likely to be filled with fluid, and
which has not been assessed in this study. Such a
phenomenon might come from the downregulation of
genes involved in the degradation process of the extra-
cellular matrix (Table S5).
The diffuse phenotype of GCCs was evaluated with
MRI in the orthotopic mice models (Fig. 4). SNU484
and Hs746T were likely to show a diffuse phenotype
in the orthotopic models. We found that the down-
regulation of CD34 is not associated with the diffuse
phenotype of SNU484 (Fig. 4). However, the high
tumorigenic potential of SNU484 cell line in the
orthotopic mice was decreased by the CD34 knock-
down from 100 to 66.7% (Table S4). SNU668 and
Hs746T show about 50 to 70% of tumorigenic poten-
tial, which remained until the end of the orthotopic
model experiments. In contrast, KATO III initially
formed a mass in the heterotopic model and disap-
peared after 2 weeks. The orthotopic model of KATO
Fig. 4 Histological difference after the suppression of CD34. a Quantification of diffuse MRI phenotype (Diffuse mice/all injected mice) and the
number of round void shape in the H&E staining. b SNU484 SC injected mouse MRI and H&E staining. c SNU484 CD34 KD MRI and H&E staining.
PI5W: Five weeks after injection of the cells. SC: scramble shRNA treated sample, KD: CD34 knockdown. Black bar indicates 50 μm with 100
x magnification
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III was not established in our BALB/c mice cohort
(Table S4).
The genes downregulated from the knockdown of
CD34 may implicate a gene set associated with the
signet-ring shape of DGCA. The Signet-ring shape is
found in the digestive tract cancers, such as esophageal
cancer, gastric cancer, and colon cancer [27–30]. And its
prognostic effect is still debatable [6, 7, 28]. And the bio-
logical component associated with the ring shape was
mucin [31, 32]. In this study, we propose the extracellu-
lar matrix related genes and lysosphingolipid-related
genes (or sphingosine-1-phosphate related genes) as the
associated genes with CD34 and the signet-ring pheno-
type [33, 34]. And recently, there are reports on the can-
cer progression with lysosphingolipid-related pathway
[35]. We speculate that targeting such vulnerabilities
would be an option for clinical researchers.
The limitation of our study is associated with the se-
lection of the animal model and the small number of
samples. We conducted our study according to the AR-
RIVE guideline to increase the transparency of our study
and minimize unnecessary animal research [36].
SNU484 was the only CD34 high expressing GCC in our
database, and it limited the extent of our study and the
generalizability of our results. Magnetic resonance im-
aging was taken at least twice for each animal for the
non-invasive evaluation, and the date was harmonized in
the same tumor cell group. However, the date of MRI
evaluation was not exactly harmonized among other
types of GCCs (Fig. 1). We were not able to see the nat-
ural survival of animals, and we euthanized the animals
when the weight of mice decreases by more than 20%
from the baseline (Fig. S8). The survival curves were cal-
culated with the tumor volume as the surrogate marker
without definite statistical significance (Fig. S9, P =
0.051). The CD34 knockdown was not associated with
the different response against 5-FU or oxaliplatin in this
study (Fig. S10). And we omitted the administration
dose-response relationship in our study.
Conclusions
We evaluated the knockdown effect of CD34 in the hu-
man gastric cancer cell, SNU484, within the BALB/c
nude mice models. The most dominant effect was the
loss of round-void shape in the H&E staining of the ex-
tracted tumor. Such phenotype may come from the
genes involved in the remodeling of the extracellular
matrix.
Fig. 5 The down-regulated signatures after the CD34 suppression. RNAseq-based differential expression of genes downregulated in the SNU484
CD34 KD cells. The larger size and the light color indicate the number of hit genes. Three stars P < 0.0001, Two stars P < 0.01, One star P < 0.05
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